Vareniclina

Revista Chilena de Enfermedades Respiratorias

Peña G., Pedro¹  Zagolin B., Mónica¹ 

[1] Clínica Santa María, Chile

关键词: Smoking cessation;    nicotinic antagonists;    varenicline;    bupropion;    nicotine.;   

DOI  :  10.4067/s0717-73482017000300212

学科分类：社会科学、人文和艺术（综合）

来源: Sociedad Chilena de Enfermedades Respiratorias

【 摘 要 】

Varenicline is a first-line therapy cessation of smoking, and has the highest effectiveness widely demonstrated in clinical trials with drop-out figures per year of the order of 25-35%. In the most recent effectiveness review conducted by the Cochrane, 39 trials were evaluated that randomized varenicline versus placebo and compared with nicotine substitutes (NRT) and bupropion. With varenicline, a RR of 2.24 was observed for abstinence at 6 months or longer at standard doses (2 mg daily) versus placebo. The RR of varenicline versus placebo compared with bupropion or NRT was 1.3 and 1.25 respectively showing its superiority once again. When the use of varenicline was evaluated for a period longer than 12 weeks, it was observed that the drug was well tolerated suggesting that its use is feasible without intensifying the adverse effects.

【 授权许可】

CC BY